Quick Answer
Evofem Biosciences, Inc. reported Total Assets of $23.79 million for the year ending 2024.
- Evofem Biosciences, Inc. showed an increase of +125.4% in Total Assets from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2014 to 2024 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $71.92 million | Q2 2015: $64.19 million | Q3 2015: $52.67 million | Q1 2016: $25.53 million | Q2 2016: $22.58 million | Q3 2016: $15.21 million | Q1 2017: $10.73 million | Q2 2017: $8.21 million | Q3 2017: $6.25 million | Q1 2018: $8.99 million | Q2 2018: $26.17 million | Q3 2018: $15.03 million | Q1 2019: $3.23 million | Q2 2019: $54.42 million | Q3 2019: $38.99 million | Q1 2020: $15.65 million | Q2 2020: $135.06 million | Q3 2020: $112.33 million | Q1 2021: $93.46 million | Q2 2021: $108.75 million | Q3 2021: $67.43 million | Q1 2022: $34.57 million | Q2 2022: $53.47 million | Q3 2022: $42.28 million | Q1 2023: $26.03 million | Q2 2023: $14.07 million | Q3 2023: $13.32 million | Q1 2024: $8.22 million | Q2 2024: $8.55 million | Q3 2024: $23.94 million | Q4 2024: $23.79 million | Q1 2025: $12.88 million | Q2 2025: $14.38 million | Q3 2025: $13.81 million.
- Over the full 11 years of available data (2014 to 2024), Evofem Biosciences, Inc.'s Total Assets has declined by 69.1%.
- Historical annual values: Fiscal year 2024: $23.79 million | Fiscal year 2023: $10.55 million | Fiscal year 2022: $25.16 million | Fiscal year 2021: $42.51 million | Fiscal year 2020: $109.97 million | Fiscal year 2019: $28.30 million | Fiscal year 2018: $4.01 million | Fiscal year 2017: $3.95 million | Fiscal year 2016: $12.82 million | Fiscal year 2015: $40.11 million | Fiscal year 2014: $76.90 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: